Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Angiotensin IV is Induced in Experimental Autoimmune Encephalomyelitis but Fails to Influence the Disease.
The top clinical trial opportunities in therapeutic apheresis and neurology.
Strategies for regeneration of components of nervous system: scaffolds, cells and biomolecules.
Disease-modifying therapies and infectious risks in multiple sclerosis.
Demyelination and Neurodegeneration in Multiple Sclerosis: The Role of Hypoxia.
Similar genetics of adult and pediatric MS: Age is just a number.
Cost effectiveness of a pragmatic exercise intervention (EXIMS) for people with multiple sclerosis: economic evaluation of a randomised controlled trial.
Fine-tuning of type I IFN-signaling in microglia - implications for homeostasis, CNS autoimmunity and interferonopathies.
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
Microsomal prostaglandin E synthase-1 aggravates inflammation and demyelination in a mouse model of multiple sclerosis.
Next-generation sequencing in understanding complex neurological disease.
Understanding tremor in multiple sclerosis: prevalence, pathological anatomy, and pharmacological and surgical approaches to treatment.
TRPV1 Gates Tissue Access and Sustains Pathogenicity in Autoimmune Encephalitis.
Transglutaminase 2 and neuroinflammation.
Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis.
Targeting Dynamic Balance in Falls-Prevention Interventions in Multiple Sclerosis: Recommendations from the International MS Falls Prevention Research Network.
Mesenchymal Stem Cells and Induced Pluripotent Stem Cells as Therapies for Multiple Sclerosis.
Case of Type 1 Diabetes Mellitus Following Interferon β-1a Treatment for Multiple Sclerosis.
Reliability of Longitudinal Brain Volume Loss Measurements between 2 Sites in Patients with Multiple Sclerosis: Comparison of 7 Quantification Techniques.
Mitochondrial mutations of Leber's hereditary optic neuropathy: a risk factor for multiple sclerosis.
Multiple sclerosis in 2015: Managing the complexity of multiple sclerosis.
The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions.
Closing the quality gap: revisiting the state of the science (vol. 4: medication adherence interventions: comparative effectiveness).
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.

Pages